Key Insights

Highlights

Success Rate

92% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 40/100

Termination Rate

3.3%

2 terminated out of 61 trials

Success Rate

92.3%

+5.7% vs benchmark

Late-Stage Pipeline

21%

13 trials in Phase 3/4

Results Transparency

25%

6 of 24 completed with results

Key Signals

6 with results92% success

Data Visualizations

Phase Distribution

48Total
Not Applicable (30)
P 2 (5)
P 3 (2)
P 4 (11)

Trial Status

Completed24
Recruiting20
Not Yet Recruiting13
Terminated2
Enrolling By Invitation1
Withdrawn1

Trial Success Rate

92.3%

Benchmark: 86.6%

Based on 24 completed trials

Clinical Trials (61)

Showing 20 of 20 trials
NCT07856238Not Yet RecruitingPrimary

Long-Term Effectiveness and Safety of Sacral Neuromodulation With InterStim for Lower Urinary Tract Dysfunction

NCT06944392Not ApplicableCompletedPrimary

Evaluating Pumpkin Seed Oil Extract Supplementation on Bladder Function

NCT07540273Not ApplicableRecruitingPrimary

Effectiveness of Ambulatory Transcutaneous Tibial Nerve Stimulation for Overactive Bladder

NCT07335484Not ApplicableRecruiting

Aquarius Pilot Study to Evaluate the New Axonics Trial System

NCT06789406Not ApplicableRecruiting

PMCF Study of the Axonics SNM System Model 5101 (R20) for the Indication of OAB

NCT07300904Not ApplicableRecruitingPrimary

Tensi+ for Treating Overactive Bladder

NCT06659536Not ApplicableRecruitingPrimary

Cefar URO - Symptomatic Treatment of Overactive Bladder

NCT07788560Not ApplicableNot Yet RecruitingPrimary

Peroneal Neuromodulation vs Pelvic Floor Exercises in OAB

NCT07781033Not ApplicableNot Yet RecruitingPrimary

Impact of Transcutaneous Electrical Nerve Stimulation on the Autonomic Nervous System in the Treatment of Overactive Bladder

NCT07780786Phase 3Not Yet RecruitingPrimary

Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder

NCT07553065Phase 2RecruitingPrimary

RELIEVE Study: NT 201 Intravesical Administration Using Vibe System (ViXe Combination Product) for the Treatment of Idiopathic Overactive Bladder

NCT06953271Phase 4RecruitingPrimary

Methenamine Hippurate Following Intradetrusor OnabotulinumtoxinA Injection

NCT07773532Not Yet RecruitingPrimary

Predictive Value of Inflammatory Biomarkers for Mirabegron Response in Women With Overactive Bladder

NCT07736560CompletedPrimary

Effect of Antimuscarinic Treatment on Premature Ejaculation Severity in Men With Overactive Bladder: a Prospective Comparison With Mirabegron

NCT07740668Not ApplicableNot Yet Recruiting

Efficacy of Transcutaneous Electrical Stimulation Therapy in the Treatment of Overactive Bladder Developing After Stroke

NCT07728747Not ApplicableCompletedPrimary

Bladder Training With or Without Biofeedback-Assisted Pelvic Floor Muscle Training for Women With Wet Overactive Bladder

NCT07711808Phase 4Not Yet RecruitingPrimary

Burden and Efficacy of Anticholinergic vs Mirabegron in Overactive Bladder - A Randomized Controlled Study

NCT07707791Not ApplicableNot Yet RecruitingPrimary

Pretibial TENS for Pain and Anxiety During Intravesical OnabotulinumtoxinA Injection

NCT07195656Not ApplicableRecruitingPrimary

Evaluation of a Non-Implanted Electrical Stimulation Device for Overactive Bladder (OAB)

NCT07405554Phase 2RecruitingPrimary

Zinc Supplementation With Botulinum Toxin for Overactive Bladder

Scroll to load more

Research Network

Activity Timeline